SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.

Shin Nippon Biomedical Laboratories, Ltd.

Equities

2395

JP3379950003

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
1,502 ^JPY	+1.49%		+5.55%	-11.54%

Feb. 02	Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024	CI
Jan. 18	Shin Nippon's STS101 Faces Regulatory Hurdle, FDA Requests Refinement for Approval	MT

Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024

February 01, 2024 at 09:30 pm EST

Shin Nippon Biomedical Laboratories, Ltd. provided consolidated earnings guidance for the year ending March 31, 2024. For the period, the company expects revenue of ¥26,190 million, Operating profit of ¥3,470 million, Profit attributable to owners of parent of ¥3,975 million or ¥95.47 basic per share.

Latest news about Shin Nippon Biomedical Laboratories, Ltd.

Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024	Feb. 01	CI
Shin Nippon's STS101 Faces Regulatory Hurdle, FDA Requests Refinement for Approval	Jan. 18	MT
Shin Nippon Biomedical Laboratories, Ltd. Announces Interim Dividend for the Year Ending March 31, 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Year Ending March 31, 2024	Nov. 07	CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024	23-08-01	CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024	23-08-01	CI
Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific Meeting	23-06-15	CI
Shin Nippon Biomedical Laboratories, Ltd. completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers.	23-06-07	CI
Jefferies Upgrades Shin Nippon Biomedical Laboratories to Buy From Hold, Adjusts Price Target to 2,800 Yen From 2,300 Yen	23-05-29	MT
Shin Nippon Biomedical Laboratories, Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-08	CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024	23-05-08	CI
Shin Nippon Biomedical Laboratories, Ltd. Announces Year End Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023	23-05-08	CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024	23-05-08	CI
Jefferies Downgrades Shin Nippon Biomedical Laboratories to Hold From Buy, Adjusts Price Target to 2,300 Yen From 3,800 Yen	23-04-18	MT
Shin Nippon Biomedical to Make $30 Million Offer for US-based Satsuma Pharmaceuticals	23-04-18	MT
Sector Update: Health Care Stocks Higher Premarket Monday	23-04-17	MT
Bank Earnings in Focus as US Equity Futures Tread Water	23-04-17	MT
Top Premarket Gainers	23-04-17	MT
Satsuma Pharmaceuticals to be Acquired by Shin Nippon Biomedical	23-04-17	MT
Shin Nippon Biomedical Laboratories, Ltd. entered into an agreement to acquire the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers for $27.6 million.	23-04-16	CI
Shin Nippon Biomedical Laboratories, Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	23-01-31	CI
Shin Nippon Biomedical Laboratories, Ltd. Revises Year End Dividend Guidance for the Year Ending March 31, 2023	23-01-31	CI
Shin Nippon Biomedical Laboratories, Ltd. Announced Dividend for the Second Quarter of Fiscal Year Ending March 31, 2023, Commence Payments from November 30, 2022	22-10-31	CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023	22-10-31	CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023	22-10-31	CI
Shin Nippon Biomedical Laboratories, Ltd. Announces Dividend on Retained Earnings, Effective November 30, 2022	22-10-31	CI

Chart Shin Nippon Biomedical Laboratories, Ltd.

Duration

Period

Chart Shin Nippon Biomedical Laboratories, Ltd.

More charts

Company Profile

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Shin Nippon Biomedical Laboratories, Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1,502 JPY

Average target price

3,150 JPY

Spread / Average Target

+109.72%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.	-11.54%	397M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research